BiOrion is a Dutch clinical stage biopharmaceutical company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases.
Biorion is currently developing a PET-imaging diagnostic for NASH/liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for metastatic colon cancer. The Biorion platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides and VHH nanobodies.
More info: www.biorion.com